消化器内科 論文(2020年)
英語論文
| 著者 | タイトル | ジャーナル |
| Tomoya Yokota, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Hiroki Hara, Takashi Ura, Takashi Kojima, Keisho Chin, Shuichi Hironaka, Takayuki Kii, Yasushi Kojima, Yasunori Akutsu, Hisayuki Matsushita, Kentaro Kawakami, Keita Mori, Takashi Makiuchi, Rie Nagumo, Yuko Kitagawa | A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. | Ann Surg Oncol. |
| Shibata M, Fukahori M, Kasamatsu E, Machii K, Hamauchi S. | A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer. | Adv Ther. |
| Hamauchi S, Yokota T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Onitsuka T, Yasui H. | Chemoradiotherapy for high-risk stage II laryngeal cancer. | Int J Clin Oncol. |
| Yamazaki K, Matsumoto S, Imamura CK et al. | Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. | Jpn J Clin Oncol. |
| Hiromichi Shirasu, Tomoya Yokota, Takeshi Kawakami, Satoshi Hamauchi, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Keita Mori, Tetsuro Onitsuka. | Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil | Int J Clin Oncol. |
| Tomoya Yokota, Masayuki Shibata, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Takeshi Kawakami, Mitsuhiro Furuta, Hiroto Inoue, Kunihiro Fushiki, Tetsuro Onitsuka | Feasibility and efficacy of chemoradiotherapy with concurrent split‑dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5‑fluorouracil for locally advanced head and neck cancer | Mol Clin Oncol. |
| Tomoya Yokota, Yuko Kitagawa | How Should the Patients with Locally Advanced Unresectable Esophageal Cancer Be Treated with Multidisciplinary Approach? | Ann Surg Oncol. |
| Tomoya Yokota, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tetsuro Onitsuka | How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment? | Current Oncology Reports . |
| Tomoya Yokota, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi | Immunotherapy for squamous cell carcinoma of the head and neck. | Jpn J Clin Oncol. |
| Tsushima T, Kasai H, Tanigawara Y. | Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer. | Cancer Chemother Pharmacol. |
| Kito Y, Satake H, Taniguchi H, Yamada T, Horie Y, Esaki T, Denda T, Yasui H, Izawa N, Masuishi T, Moriwaki T, Mori K, Yamazaki K. | Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. | Cancer Chemother Pharmacol. |
| Todaka A, Nara S, Motoi F, Morinaga S, Toshiyama R, Higuchi R, Konishi M, Shirakawa H, Tsumura H, Okuyama H, Nagano H, Shioji K, Sugimachi K, Asagi A, Mizuno N, Furuse J. | Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. | Anticancer Res. |
| Hidenori Kimura, Satoshi Hamauchi, Sadayuki Kawai, Yusuke Onozawa, Hirofumi Yasui, Aiko Yamashita, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Tomoya Yokota | Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck. | Int J Clin Oncol. |
| Hiroto Inoue, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Takeshi Kawakami, Hiromichi Shirasu, Akifumi Notsu, Hirofumi Yasui, Tetsuro Onitsuka | Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. | Auris Nasus Larynx. |
| Masaki Takinami, Tomoya Yokota. | Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma. | Case Rep Oncol |
| Hiromichi Shirasu, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tetsuro Onitsuka, Takashi Yurikusa, Keita Mori, Hirofumi Yasui | Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer | BMC Cancer. |
| Yamanaka T, Yamazaki K, Hamano T. | [Using Real World Data in Cancer Clinical Studies]. | Gan To Kagaku Ryoho. |
| Taniguchi H, Yamanaka T, Sakai D, Muro K, Yamazaki K, Nakata S, Kimura H, Ruff P, Kim TW, Peeters M, Price T. | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. | Cancers (Basel). |
| Shitara K, Yamazaki K, Tsushima T, Naito T, Matsubara N, Watanabe M, Sarholz B, Johne A, Doi T. | Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. | Jpn J Clin Oncol. |
| Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii T, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J. | Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). | Oncologist. |
| Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. | Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). | Eur J Cancer. |
| Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. | Nat Med. |
| Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. | Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. | nt J Clin Oncol. |
| Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. | Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. | BMC Cancer. |
| Masuishi T, Nakajima TE, Yamazaki K, Hironaka S, Kudo C, Yoshimura K, Muro K. | WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases | Future Oncol. |
| Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, Tsuji A, Moriwaki T, Tanioka H, Shinozaki K, Uchino K, Yasui H, Tsukuda H, Nishikawa K, Ishida H, Yamanaka T, Yamazaki K, Hironaka S, Esaki T, Boku N, Hyodo I, Muro K. | Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). | J Clin Oncol. |
| Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | Int J Clin Oncol |
| Masuishi T, Nakajima TE, Yamazaki K, Hironaka S, Kudo C, Yoshimura K, Muro K. | WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases | Future Oncol |
| Ebi H, Bando H, Taniguchi H, Sunakawa Y, Okugawa Y, Hatanaka Y, Hosoda W, Kumamoto K, Nakatani K, Yamazaki K. | Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition | Cancer Sci |
| Ito T, Sugiura T, Okamura Y, Yamamoto Y, Ashida R, Ohgi K, Yasui H, Yamazaki K, Uesaka K. | The Safety and Survival Outcome of Hepatectomy with Combined Bile Duct Resection for Colorectal Liver Metastasis | World J Surg |
| Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii T, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J. | Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study) | Oncologist |
| Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Kusaba H, Okamura S, Tsuda M, Tamura T, Shinozaki K, Tsushima T, Tsuda T, Shirakawa T, Yamashita H, Morita S, Hironaka S, Muro K. | Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study | Medicine (Baltimore) |
| Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K. | Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group | BMC Cancer |
| Izawa N, Shitara K, Yonesaka K, Yamanaka T, Yoshino T, Sunakawa Y, Masuishi T, Denda T, Yamazaki K, Moriwaki T, Okuda H, Kondoh C, Nishina T, Makiyama A, Baba H, Yamaguchi H, Nakamura M, Hyodo I, Muro K, Nakajima TE. | Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G) | Target Oncol |
| Furuta M, Watanabe J, Aramaki T, Notsu A, Yasui H. | Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies | In Vivo |
| Booka E, Haneda R, Ishii K, Kawakami T, Tsushima T, Yasui H, Onoe T, Ogawa H, Tsubosa Y. | Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma | Ann Surg Oncol |
| Kato K, Doki Y, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Kudo T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Kitagawa Y. | Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer | Cancer Sci |
| Nakamura K, Hatakeyama K, Furukawa K, Fujiya K, Kamiya S, Hikage M, Tanizawa Y, Bando E, Ohshima K, Urakami K, Machida N, Yasui H, Yamaguchi K, Terashima M. | Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis | Gastric Cancer |
| Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K. | Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial | JAMA Oncol |
| Doi T, Boku N, Onozawa Y, Takahashi K, Kawaguchi O, Ohtsu A. | Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies | Invest New Drugs |
| Yokota T, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R; Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group. | Immunotherapy for squamous cell carcinoma of the head and neck | Jpn J Clin Oncol |
| Nomura M, Oze I, Masuishi T, Yokota T, Satake H, Iwasawa S, Kato K, Andoh M. | Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma | Int J Clin Oncol |
| Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator’s choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Head Neck |
| Sugiura T, Uesaka K, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Asakura H, Todaka A, Fukutomi A. | Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma | Ann Gastroenterol Surg |
| Morinaga S, Takita M, Yoshizawa A, Kamei K, Nakamori S, Ishihara S, Kuramochi H, Yokoyama Y, Uchiyama T, Murohisa G, Ishigaki M, Todaka A, Fukutomi A. | FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06 | Pancreas |
| Imamura T, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Ohgi K, Todaka A, Fukutomi A, Sato R, Aramaki T, Uesaka K. | Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer | Langenbecks Arch Surg |
| Kobayashi N, Omae K, Horita Y, Ueno H, Mizuno N, Uesugi K, Sudo K, Ozaka M, Hayashi H, Okano N, Kamei K, Yamaguchi A, Kobayashi S, Suzuki S, Ishihara S, Uchiyama T, Todaka A, Fukutomi A. | FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan | Pancreatology |
| Hironaka S, Komori A, Machida R, Ito Y, Takeuchi H, Ogawa G, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Nozaki I, Ura T, Chin K, Fukuda H, Kitagawa Y. | The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909 | Esophagus |
| Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T. | TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma | BMC Cancer |
| Fushiki K, Matsubayashi H, Sasaki K, Uesaka K. | Rare Images of a Peripancreatic Ganglioneuroma | Intern Med |
和文論文
| 著者 | タイトル | ジャーナル | |
| 古田 光寛、山崎 健太郎 | ハイリスクstage II結腸がん術後補助化学療法における最新のエビデンスを読み解く | (1881-6568)25巻6号 Page680-686(2020.06) | |
| 白数 洋充 | 【消化管がん】血液循環腫瘍DNAスクリーニングにもとづく術後MRD(minimal residual disease)に対する臨床開発の現状と展望 | 腫瘍内科 | (1881-6568)25巻6号 Page660-666 |
| 横田 知哉 | 【がん免疫療法の最前線】免疫チェックポイント阻害薬の有害事象の特徴と対策 | JOHNS | (0910-6820)36巻4号 Page455-458 |
| 伏木 邦博、對馬 隆浩 | 胃がんおよび食道がんの免疫療法と分子標的治療の進歩 | がん分子標的治療 | Vol.18 No.2, 20-26 |